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Abstract Menkes disease (MD) is an X-linked recessive
disorder characterized by copper deficiency resulting in a
diminished function of copper-dependent enzymes. Most
MD patients die in early childhood, although mild forms of
MD have also been described. A diversity of mutations in
the gene encoding of the Golgi-resident copper-transport-
ing P1B-type ATPase ATP7A underlies MD. To elucidate
the molecular consequences of the ATP7A mutations,
various mutations in ATP7A associated with distinct phe-
notypes of MD (L873R, C1000R, N1304S, and A1362D)
were analyzed in detail. All mutants studied displayed
changes in protein expression and intracellular localization
parallel to a dramatic decline in their copper-transporting
capacity compared to ATP7A the wild-type. We restored
these observed defects in ATP7A mutant proteins by cul-
turing the cells at 30C, which improves the quality of
protein folding, similar to that which as has recently has
been demonstrated for misfolded ATP7B, a copper trans-
porter homologous to ATP7A. Further, the effect of the
canine copper toxicosis protein COMMD1 on ATP7A
function was examined as COMMD1 has been shown to
regulate the proteolysis of ATP7B proteins. Interestingly,
in addition to adjusted growth temperature, binding of
COMMD1 partially restored the expression, subcellular
localization, and copper-exporting activities of the ATP7A
mutants. However, no effect of pharmacological chaper-
ones was observed. Together, the presented data might
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provide a new direction for developing therapies to
improve the residual exporting activity of unstable ATP7A
mutant proteins, and suggests a potential role for COM-
MD1 in this process.
Keywords ATP7A  Copper  COMMD1  Menkes
disease  Pharmacological chaperones  Protein folding
Abbreviations
ATOX1 Antioxidant protein 1
ATP7A ATP-dependent copper transporter 7A
ATP7B ATP-dependent copper transporter 7B
ATP8B1 P-type ATPase member 8B1
BCS Bathocuproinedisulfonic acid





GST PD GST pull-down
IB Immunoblotting
MD Menkes disease
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MRE Metal-responsive element
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The transition metal copper is an essential trace element
required for a range of cellular processes, including
neurotransmitter synthesis, mitochondrial respiration,
antioxidant defense, connective tissue formation, pig-
mentation, peptide amidation, and iron metabolism
(reviewed by [1]). The significance of copper is dra-
matically illustrated by the X-linked recessive disorder
Menkes disease (MD; OMIM #309400), which is char-
acterized by copper deficiency (reviewed by [2–4]).
Based on the severity of the phenotype, three classes of
MD can be distinguished. Classical MD patients die in
early childhood and suffer from severe mental retardation
accompanied by epileptic insults, growth retardation,
hypothermia, hypopigmentation, laxity of skin and joints,
and the typical ‘‘kinky’’ or steely hair [4]. Patients dis-
playing less severe or even no neurological defects are
classified as mild MD or occipital horn syndrome (OHS),
in which the clinical features of OHS are primarily
related to defects in connective tissue formation [4].
MD results from mutations in ATP7A, encoding a
165-kDa copper-transporting P1B-type ATPase [5–10].
Although the copper uptake from the diet into entero-
cytes is not disturbed in patients with MD, dysfunction
of ATP7A affects copper transport across the intestinal
mucosa into the blood and across the blood–brain bar-
rier, leading to copper deficiency in many tissues.
ATP7A resides in the trans-Golgi network (TGN), where
it mediates copper incorporation into copper-dependent
enzymes such as tyrosinase, lysyl oxidase, and peptidyl-
a-monooxygenase. Upon increasing copper concentra-
tions, ATP7A translocates to the plasma membrane (PM)
to facilitate cellular copper excretion [2, 11, 12]. ATP7A
missense mutations within conserved regions of the P1B-
type ATPase family generally lead to the development of
MD, and are associated with dysregulation of ATP7A
protein synthesis, stabilization, trafficking, intracellular
localization, copper-transporting capacity, and post-
translation modifications (reviewed by [3]). Indeed,
mutations in the DKTG-motif (Fig. 1a), containing a
conserved aspartic acid residue indispensable for ATP7A
activity, affect the copper-induced translocation of
ATP7A from the TGN to the PM. A comparable phe-
notype is seen when the copper-binding CPC-motif
(Fig. 1a), characteristic for heavy metal transporting
P-type ATPases, is mutated. However, a clear correlation
between mutations in ATP7A and MD phenotype has not
yet been identified [10].
ATP7A is highly homologous to ATP7B, which is
another member of the P1B-type ATPase family. ATP7B is
involved in copper export from hepatocytes into the bile [2,
3]. Mutations in ATP7B are associated with the hepatic
copper overload disorder Wilson’s disease (WD; OMIM
#277900), and can lead to misfolded, unstable proteins that
mislocalize and consequently are impaired in their copper-
transporting function. Interestingly, these defects can be
partially restored by adjusting growth temperature or by
addition of pharmacological chaperones [13]. In addition,
we have previously demonstrated a role for COMMD1,
encoded by the canine copper toxicosis gene COMMD1, in
ATP7B protein stability. We speculated that COMMD1
mediates the proteolysis of misfolded, newly synthesized
ATP7B proteins [14], and thus might be involved in the
pathogenesis of WD.
In the present study, we characterized the molecular
consequences of a number of ATP7A mutations that are
associated with distinct phenotypes of MD (L873R,
C1000R, N1304S, and A1362D). We investigated whether
150 W. I. M. Vonk et al.
123
defects in mutant protein expression, subcellular localiza-
tion, and copper-transporting function as a result of the
mutation can be improved, similar as was previously
demonstrated for ATP7B. In addition, the effect of
COMMD1 on the molecular function of ATP7A WT and
mutants was studied.
Fig. 1 Copper-dependent interaction of ATP7A mutant proteins with
ATOX1 is unaffected despite their variations in protein expression.
a Schematic representation of distinct functional domains in ATP7A.
ATP7A contains eight trans-membrane spanning helices. At the
N-terminus, six metal binding sites (MxCxxC-motifs) are located
where each can bind one Cu? ion. The nucleotide-binding domain,
containing the conserved SEHPL-motif and DKTG-motif, is located
in the cytosolic loop between TMD 6 and 7. After ATP binding and
hydrolysis by the SEHPL-motif, the aspartic acid in the DKTG-motif
accepts the phosphate group, resulting in the formation of a
phosphorylated intermediated ATP7A protein. The actuator domain
contains the TGE-motif, which is involved in dephosphorylation of
the protein. The LL-motif at the end of the C-terminus regulates
retrograde transport of the protein from vesicles or the plasma
membrane (PM) to the trans-Golgi network (TGN). ATP7A mutations
studied in this report are depicted with a yellow star. b HEK293T
cells were transiently transfected with constructs encoding pcDNA
(empty vector; EV), ATP7A-flag wild-type (WT) or mutant (L873R,
C1000R, 1304S, and A1362D) as indicated. Protein lysates (30 lg)
were analyzed by SDS-PAGE and immunoblotting (IB) using
antibodies directed against the Flag-tag or a-Tubulin as indicated
on the right side of the figure. c mRNA abundance of ATP7A-Flag
WT or mutants, expressed in HEK293T cells, was analyzed by means
of qRT-PCR as described in ‘‘Materials and methods’’. The data
represent mean ± SD of triplicate measurements for each condition.
The data were corrected for transfection efficiency and GAPDH
expression, and normalized to WT. d HEK293T cells were transiently
transfected with EV or with constructs encoding ATP7A-Flag WT
and mutants, GST only or ATOX1-GST, as indicated above the
figure. Cells were incubated overnight under basal conditions (-) or
with 150 lM CuCl2. Cells were lysed (lysis buffer supplemented with
1 mM CuCl2) and GST fusion proteins were precipitated using
glutathione Sepharose (GSH) beads. Precipitates (GST PD) or total
cell lysates (Input; 30 lg) were analyzed by SDS-PAGE and IB using
antibodies directed against the Flag-tag or GST




The following antibodies were used for immunoprecipi-
tation and immunoblotting: rabbit-anti-COMMD1
antiserum [15], polyclonal mouse-anti-Flag M2 HRP
conjugated (Sigma-Aldrich, St. Louis, MO, USA), poly-
clonal rabbit-anti-GST (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), polyclonal rabbit-anti-HA (Sigma-
Aldrich), mouse-anti-transferrin receptor (Invitrogen Life
Technologies Corporation, Carlsbad, CA, USA), goat-
anti-ATP7A (Santa Cruz), polyclonal mouse-anti-a-tubu-
lin (Sigma-Aldrich), and monoclonal mouse-anti-b-actin
(Abcam, Cambridge, MA, USA). For immunofluores-
cence, Flag-epitopes were visualized using rabbit-anti-
Flag antibody (Sigma-Aldrich), and the trans-Golgi net-
work (TGN) was labeled with mouse-anti-p230 antibody
(BD Transduction Laboratories, San Diego, CA, USA).
Secondary labeling was performed using Alexa Fluor
488- and 568-conjugated antibodies (Molecular Probes,
Eugene, OR, USA). Recombinant human lysyl oxidase
homolog 2 was obtained from R&D Systems, Inc. (Min-
neapolis, MN, USA).
A non-targeting pool of siRNAs (siControl) and siRNA
pools targeting hCOMMD1 (siCOMMD1; targeting
sequences have been described previously [16]) were
purchased as ON-TARGET plus SMART pools from
Dharmacon (Chicago, IL, USA).
Cell culture and transfections
Human embryonic kidney 293T cells (HEK293T), human
osteosarcoma cells (U2OS) (both obtained from ATCC,
Manassas, VA, USA) and mouse embryonic fibroblasts
(MEFs) were cultured in high-glucose Dulbecco’s modified
Eagle’s medium GlutaMAXTM (4.5 g/l D-Glucose
and Pyruvate; Invitrogen Life Technologies Corporation)
supplemented with 10% fetal bovine serum (FBS), L-glu-
tamine, penicillin and streptomycin at 37C in 5% CO2.
Monoclonal HEK293T cell lines, stably transfected with
pSUPER-RETRO vector (shControl) or a plasmid encod-
ing a short hairpin RNA (shRNA) targeting the COMMD1
mRNA sequence (shCOMMD1), were described previ-
ously [17] and maintained in HEK293T medium
supplemented with 1 lg/ll puromycin dihydrochloride
(Sigma-Aldrich). In various experiments, cells were incu-
bated overnight with 10–150 lM CuCl2 (Sigma-Aldrich)
or 10–200 lM bathocuproinedisulfonic acid (BCS; Sigma-
Aldrich), respectively, prior to lysis or fixation.
MEFs were isolated from E14 embryos carrying loxP
restriction sites around the first exon of Commd1. Loss of
Commd1 expression was accomplished as described pre-
viously [18].
Cells were transiently transfected by the calcium phos-
phate precipitation method as described elsewhere [19].
For cell surface biotinylation and immunofluorescence
assays, cells were transfected with linear polyethylenimine
(PEI; Polysciences, Warrington, PA, USA) at a 1:5
DNA:PEI ratio in serum-free medium. Transfection of
siRNA ON-TARGETplus SMARTpools was performed by
means of Lipofectamine RNAiMAX (Invitrogen Life
Technologies Corporation), according to the manufac-
turer’s protocol. Cells were harvested 48 h after
transfection for biochemical analysis.
Constructs
pEBB-HA-COMMD1 and pEBB-COMMD1-GST con-
structs have been described previously [20]. pEBB-
COMMD1-GST a.a. 1–118 and a.a. 119–190 deletion
constructs were kindly provided by Dr. E. Burstein
(Dallas, TX, USA) [21]. pcDNA4-ATP7A-Myc construct
was obtained from Dr. A. Monaco (Oxford, UK) [22] in
which the Flag-tag sequence was introduced in front of
the Myc-tag by the Quickchange site-directed mutagen-
esis method (Stratagene, La Jolla, CA, US). ATP7A-Flag
deletion constructs (a.a. 1–654, a.a. 795–94, a.a.
1,008–1,368, and a.a. 1,411–1,500) were subcloned into
the pEBB-Flag vector. MD-associated mutations (L873R,
C1000R, N1304S, and A1362D) were introduced in
pcDNA4-ATP7A-Flag-Myc by the Quickchange site-
directed mutagenesis method (primer sequences available
upon request). Sequences were verified by automated
sequence analysis. The pG3L3-E1b-TATA-4MRE con-
struct (MRE luciferase reporter) has been described
previously [23], whereas the pRL-TK construct was
obtained commercially from the Promega Corporation
(Madison, WI, USA).
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from cells by means of TRIZOL
(Invitrogen Life Technologies Corporation). cDNA syn-
thesis was performed using random hexamers and Super
Script II reverse transcriptase (Invitrogen Life Technologies
Corporation). mRNA expression of ATP7A was analyzed
by quantitative PCR using Sybrgreen (Bio-Rad Laborato-
ries Inc, Hercules, CA, USA) and the MyIQ real-time PCR
cycler (Bio-Rad) using primers listed in Supplementary
Table 1. Results were presented as fold induction, and
normalized to the expression of GAPDH, which was
selected as the most stable reference gene. Zeocin mRNA
expression was used as a transfection marker.
152 W. I. M. Vonk et al.
123
Metal-responsive element—luciferase copper biosensor
assays
The bioavailability of cytosolic copper was measured by
MRE-luciferase copper reporter assays, which were per-
formed as described previously [13, 23]. Briefly, 20,000
HEK293T cells were seeded in 96-well plates and co-
transfected with 35 ng pG3L3-E1b-TATA-4MRE con-
struct (MRE-luciferase reporter), 0.25 ng or pRL-TK
vector and 0.4 ng empty vector (EV) or pcDNA4-ATP7A
constructs as indicated. Cells were incubated overnight
with indicated concentration of CuCl2, whereafter the cells
were rinsed in PBS and harvested in passive lysis buffer
(Promega) according to the manufacturer’s protocol.
Samples were analyzed by luminometry (Berthold Tech-
nologies, Bad Wildbad, Germany) using the Dual-
Luciferase reporter system (Promega) for firefly luciferase
activity and Renilla luciferase activity, according to the
manufacturer’s protocol. The RLU (relative light units)
were calculated by dividing firefly luciferase measurements
by Renilla luciferase measurements. All values were
expressed as fold induction relative to ATP7A WT.
GST pull-down assays and immunoblot analysis
Precipitation of GST-tagged proteins by means of
GSH-Sepharose beads was performed as described in [24].
In short, transiently transfected cells were rinsed once in
PBS prior to lysis in lysis buffer A (25 mM HEPES; pH
7.9, 100 mM NaCl, 1 mM NaEDTA, 1% Triton X-100,
10% glycerol) supplemented with 1 mM Na3VO4, 1 mM
PMSF, 10 mM DTT, and protease inhibitors (Complete;
Roche, Basle, Switzerland). For lysis of copper-treated or
BCS-treated cells, lysis buffer A was supplemented with
1 mM CuCl2 or BCS, respectively [14, 25]. Protein con-
centrations were determined by Bradford Protein Assay
(Bio-Rad). In all interaction studies, equal amounts of
proteins in lysis buffer A were used for precipitation.
Input samples represented approximately 1% of protein
amounts used for GST-precipitation. Except for detection
of ATP7A, protein lysates were boiled at 95C prior to gel
loading. In all experiments, SDS-PAGE was followed by
protein transfer onto nitrocellulose membranes (Schleicher
& Schuell’s-Hertogenbosch, the Netherlands) for immu-
noblot analysis.
Cell surface biotinylation assays
U2OS cells were used for cell surface biotinylation assays.
Cells were incubated under basal conditions, or overnight
with 50 lM CuCl2 as indicated in the experiment. Two
days after transfection, proteins present on the cell surface
were biotinylated as described in [26].
Lysyl oxidase activity assays
For lysyl oxidase activity assays, 20,000 HEK293T cells,
stably transfected with either shControl or shCOMMD1,
were seeded in 96-well plates. Upon overnight incubation
with 10 and 50 lM BCS, or 0, 10, and 50 lM CuCl2, the
lysyl oxidase activity was measured according to the
manufacturer’s protocol using the AmpliteTM Fluorimetric
Lysyl Oxidase Assay Kit (AAT Bioquest, Inc., Sunnyvale,
CA, USA), in which released H2O2 is detected using an
AmpliteTM HRP substrate. Obtained values were plotted
against a lysyl oxidase standard curve.
Indirect immunofluorescence and confocal laser-
scanning microscopy
HEK293T cells were grown on coverslips pre-coated with
poly-L-lysine (1:10 dilution, Sigma-Aldrich). Forty-eigh-
t hours after transfection, cells were washed once in ice-
cold PBS and fixed using 4% (w/v) paraformaldehyde for
20 min at 4C. Cells were quenched with 50 mM NH4Cl
for 5 min at room temperature following blocking and
permeabilization using blocking buffer (0.2% (w/v) BSA
(Sigma-Aldrich), 0.1% (w/v) saponin (Sigma-Aldrich) in
PBS) for 1 h at room temperature in the dark. Immunola-
beling was performed in blocking buffer with the indicated
primary antibodies for 1 h. After washing three times,
secondary labeling was performed with AffiniPure Alexa
Fluor 488 or 568 antibodies. DAPI staining was per-
formed in the final wash steps preceding the mounting of
coverslips in Fluorsave (VWR International Ltd, Leices-
tershire, UK). Images were acquired using an LSM710
Meta confocal microscope (Carl Zeiss, Jena, Germany)
equipped with a 63X/1.40 N.A. Plan-Apochromat objec-
tive by sequential excitation at 408, 488, and 561 nm.
Statistical analysis
Relative protein expressions and interaction strengths were
quantified using densitometry (GS-700; Bio-Rad). The
quantitative data in this paper are represented as
mean ± SD. Statistical evaluation was made using Stu-
dent’s t test and differences were considered to be
significant at p \ 0.05.
Results
Menkes disease-associated mutations in ATP7A result
in diminished copper-transporting capacities
For this study, we selected mutations in ATP7A, which are
associated with either classical MD (L873R), mild MD
COMMD1 modulates ATP7A function 153
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(C1000R and A1362D), or OHS (N1304S and A1362D)
(Fig. 1a, yellow stars). Several features of these mutants
have already been reported by MD patient studies and yeast
studies (summarized in Table 1). However, the detailed
molecular consequences of these mutations on ATP7A
expression, intracellular localization, and function in
eukaryotic cells remain to be determined. First, we deter-
mined the expression of the mutant ATP7A proteins
relative to the ATP7A wild-type (WT). Transient trans-
fection of HEK293T cells with ATP7A WT or mutant
constructs resulted in variable protein expression. Whereas
the expression of the L873R and N1304S mutants was
more abundant in comparison to WT, a clear decrease in
the protein expression of the C1000R and A1362D mutants
was observed (Fig. 1b). Importantly, as shown in Fig. 1c,
the differences in protein expression could not be ascribed
to alterations in the mRNA expression of the mutants rel-
ative to ATP7A WT. Despite their altered protein
expression, GST pull-down analysis showed that all
ATP7A mutants were still able to interact with the copper
chaperone ATOX1 in a copper-dependent manner, similar
to that seen for WT protein (Fig. 1d).
Second, we examined whether the mutations affected
the copper-induced translocation of ATP7A from the TGN
to the PM using indirect immunofluorescence and cell
surface biotinylation assays. As shown previously, co-
localization of ATP7A WT protein with the TGN marker
p230 demonstrated that ATP7A is localized to the TGN
under basal conditions (Fig. 2a; upper frames). In excess
copper, ATP7A WT was completely translocated to the PM
(Fig. 2a; lower frames). Interestingly, all ATP7A mutant
proteins showed an altered subcellular localization com-
pared to WT (Fig. 2b). In line with previous findings [27],
mutant L873R was found to be constitutively present at the
PM. N1304S was localized to the cell periphery and the
PM under both conditions. Similar to ATP7A WT,
C1000R, and A1362D mutants localized to the TGN;
however, upon increasing copper concentrations, all
immunoreactivity remained restricted to TGN, and no
staining at the PM could be observed, indicating that both
proteins failed to translocate to the PM. The PM
localization of ATP7A WT and the mutant proteins L873R
and N1304S was confirmed by biotinylation assays in
U2OS cells. Upon copper incubation, ATP7A WT
expression at the PM was markedly enhanced (Fig. 2c). In
agreement with the immunofluorescence data, we demon-
strated that mutant L873R is constitutively present on the
PM. Similar to ATP7A WT, biotinylation studies of mutant
N1304S revealed a copper-induced PM expression,
although its occurrence at the PM was already higher
compared to WT protein at basal conditions. Interestingly,
the re-localization of both mutants from the PM back to the
TGN was significantly affected. Mutant L873R remained
localized to the PM in conditions of copper depletion,
whereas N1304S expression was most abundant in the cell
periphery (Fig. 2d). This indicates that both mutants were
drastically impaired in their retrograde trafficking to the
TGN.
Third, we investigated whether the copper-transporting
activity of the different ATP7A mutants was affected. For
this, an established luciferase-based copper biosensor was
employed, which has previously been used to characterize
the activity of copper transporters, including ATP7B [13,
23]. The copper biosensor design is based on the transac-
tivation of the metallothionein-1 promotor in response to
bioavailable cytosolic copper. An increase in the cytosolic
copper concentration results in activation of the metal
responsive transcription factor 1 (MTF-1), and subse-
quently promotes the expression of firefly luciferase by
binding of MFT-1 to MREs positioned upstream of the
firefly luciferase open reading frame in a copper-dependent
fashion. In this way, the MRE-luciferase reporter measures
the bioavailable cytosolic copper. Upon increasing copper
concentrations, empty vector (EV) transfected cells showed
a clear and saturable induction of reporter activity (Fig. 3a,
black line). In the presence of ATP7A WT, the reporter
activity was markedly diminished, reflecting ATP7A-
dependent export of copper from the cell (Fig. 3a, dark
blue line). As shown in Fig. 3a, the copper-transporting
capacities of all the mutants were clearly impaired and
showed almost a similar induction of the copper reporter
activity upon copper stimulation as was seen for
Table 1 List of studied Menkes disease-associated ATP7A mutants and their characteristics
Mutation Affected domain Clinical phenotype Localization Cu transporting activity References
Basal Excess Cu (yeast studies)
L873R A-domain (LITGEA-motif) Classical MD CP, PM PM No copper response [27, 40]
C1000R TMD6 (CPC-motif) Mild MD TGN TGN No copper response [6, 27, 41–43]
N1304S P-domain (GDGIND-motif) OHS ND ND *33% compared to WT [44]
A1362D TMD7 OHS/mild MD TGN TGN *17% compared to WT [6, 35]
A-domain Actuator domain, P-domain phosphorylation domain, MD Menkes disease, OHS occipital horn syndrome, PM plasma membrane, CP
cell periphery, TGN trans-Golgi network, ND not determined
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Fig. 2 ATP7A mutants display
an altered subcellular
localization compared to the
wild-type protein. a HEK293T
cells were transfected with
ATP7A-Flag WT, and
incubated overnight under basal
conditions or with 150 lM
CuCl2. Cells were subsequently
analyzed by indirect confocal
immunofluorescence using
antibodies against the Flag-tag
(green). TGN was visualized by
using p230 antibodies (red) and
nuclei were stained with DAPI
(blue). Bars: 10 lm.
b Localization of ATP7A
mutants was determined as
described under Fig. 2a. Bars:
10 lm. c Cell surface
abundance of ATP7A-Flag WT
and mutants L873R and
N1304S was assessed by cell
surface biotinylation in U2OS
cells. Cells were incubated




(biotinylation) and total cell
lysates (input; 30 lg) were
analyzed by IB using the
antibodies indicated. Transferrin
(TfR) expression was used as a
positive loading control. WT,
L873R, and N1304S were
analyzed on separate
membranes. d Retrograde
trafficking of ATP7A mutants
L873R and N1304S was
analyzed as described under
Fig. 2a. Cells were incubated
overnight under basal
conditions, with 150 lM CuCl2
or with 200 lM BCS,
respectively. Bars: 10 lm
COMMD1 modulates ATP7A function 155
123
EV-transfected cells (Fig. 3a, b). These data indicate that
all ATP7A mutations studied in this paper are associated
with aberrant subcellular localization and for some muta-
tions also with reduced protein expression. Consequently,
these changes result in almost complete impairment of their
copper-transporting capacity.
Mutant protein expression is impaired as a result
of aberrant protein folding
In contrast to the enhanced expression of mutants L873R
and N1304S, the protein level of mutants C1000R and
A1362D was clearly reduced and is likely the result of
increased proteolysis. To examine the potential role of
proteasomal degradation on the decreased expression of
C1000R and A1362D, cells were transfected with each of
the mutants and incubated with the proteasomal inhibitor
MG132. Blocking the proteasomal activity markedly
improved the protein expression of both mutants (Fig. 4a),
and the enhanced proteasomal degradation of C1000R and
A1362D mutants might be the result of defective protein
folding. To test this hypothesis, we improved the quality of
the protein folding by reducing the growth temperature (as
shown previously by [13, 26, 28, 29]). HEK293T cells
transiently transfected with either WT or ATP7A mutants
C1000R and A1362D were grown at a low temperature
(30C). At 30C, the expression of ATP7A WT, C1000R,
and A1362D mutant proteins was markedly increased
compared to cells cultured at 37C (Fig. 4b). Next, we
investigated the effects of the pharmacological folding
chaperones 4-phenyl butyric acid (4-PBA) and curcumin
on mutant protein expression. Incubation with 4-PBA or
curcumin under conditions previously used to enhance the
stability of other mutant P-type ATPases (e.g., ATP7B and
ATP8B1) [13, 26], however, did not enhance the protein
expression of ATP7A C1000R and A1362D (data not
shown).
Since cellular growth at 30C restores mutant protein
expression, we determined whether protein localization and
function can similarly be rescued by lowering the growth
temperature. Although the subcellular localization of
ATP7A WT protein was unaltered by a lower growth
temperature, the intracellular localization of both mutants
was clearly normalized. As shown in Figs. 2 and 4c, the
expression of the C1000R and A1362D mutants was
mainly restricted to the TGN at 37C, whereas culture at
30C induced a clear translocation to the cell periphery
already at basal conditions (Fig. 4c). In excess copper,
translocation to the PM of mutant A1362D was induced,
similarly to ATP7A WT. Remarkably, copper reporter
assays at this temperature demonstrated a significant
decrease in the induction of the reporter to levels almost
comparable to ATP7A WT, indicating a clear enhancement
of the copper-transporting function of both ATP7A mutants
(Fig. 4d). These data therefore suggest that the reduced
copper-transporting capacities of the C1000R and A1362D
mutants result from protein misfolding and subsequent
proteasomal degradation or mislocalization.
COMMD1 binds ATP7A and improves the protein
expression of ATP7A
Previously, we and others have demonstrated that COM-
MD1 regulates the proteolysis of a number of proteins,
including ATP7B [14, 17, 30, 31]. To investigate whether
ATP7A protein stability is also mediated by COMMD1, we
studied the effect of COMMD1 on ATP7A expression.
Fig. 3 Copper-transporting capacities of ATP7A mutants are dras-
tically impaired compared to the wild-type. a HEK293T cells were
transiently transfected with the MRE-luciferase copper reporter,
together with EV (black line), ATP7A-Flag WT (dark blue line) or
mutant constructs (light blue lines). After transfection, cells were
incubated overnight with different concentrations of CuCl2 as
indicated in the graph. MRE-luciferase copper reporter activities
were measured and normalized for Renilla luciferase activity as
transfection control. MRE-luciferase copper reporter activities are
expressed as fold induction relative to WT. Values are ±SD.
b Histogram describing relative fold induction of the copper reporter
activity for EV and ATP7A WT and mutants as measured in Fig. 3a at
40 lM CuCl2
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Interestingly, overexpression of COMMD1 clearly
enhanced the level of both ATP7A WT and mutant proteins
(Fig. 5a). This effect of COMMD1 on ATP7A expression
did not result from changes in ATP7A mRNA levels
(Fig. 5b). In concordance, HEK293T cells stably trans-
fected with shRNA targeting COMMD1 sequence
(shCOMMD1) showed a decrease in ATP7A protein level
(Fig. 5c), and ATP7A WT and all tested mutants were
similarly affected by COMMD1 knockdown. These data
were confirmed in HEK293T cells transiently transfected
with siRNA targeting COMMD1 expression (Supplemen-
tary Fig. 1). In addition, shRNA-mediated downregulation
of COMMD1 expression in HEK293T cells resulted in a
significant decline in the protein level of endogenous
ATP7A compared to control cells (Fig. 5d). Similar results
were obtained in mouse embryonic fibroblasts (MEFs)
lacking Commd1 expression (Fig. 5d).
Next, we elucidated to what extent COMMD1 expres-
sion affects the cellular copper homeostasis. In line with
the observed decline in ATP7A protein level, downregu-
lation of COMMD1 significantly induced the activity of the
copper reporter. This suggests that copper efflux from the
cell, mediated by ATP7A, is attenuated in COMMD1
depleted cells (Fig. 5e), but was complemented by exoge-
nous ATP7A (Fig. 5e). To further corroborate the role of
COMMD1 on ATP7A activity, we studied the biosynthesis
of active cuproenzyme lysyl oxidase. Lysyl oxidase
activity is dependent on the copper-transporting activity of
ATP7A [32]. COMMD1 depletion resulted in significant
reduction in lysyl oxidase activity in both HEK293T
COMMD1 knockdown cells and in Commd1 KO MEFs
compared to control cells (Fig. 5f).
Subsequently, we determined whether COMMD1 also
interacts with ATP7A WT and mutant proteins, as has
previously been demonstrated for ATP7B [13, 14]. GST
PD analyses revealed a clear and specific interaction
between COMMD1 and ATP7A WT (Fig. 6a). Although
the expression of ATP7A WT and mutant proteins differed,
we could not distinguish any obvious discrepancies in the
binding of COMMD1 to ATP7A WT and mutants. Similar
to what has been shown for all of the identified COMMD1
protein–protein interactions so far [14, 30, 31, 33, 34], the
Fig. 4 Misfolding and recovery of ATP7A mutant protein expres-
sion. a HEK293T cells transiently transfected with ATP7A-Flag WT,
and mutants C1000R and A1362D were treated overnight with
DMSO or 3 lM MG132. Cells were lysed and protein expression
(30 lg) was determined by IB. b HEK293T cells were transiently
transfected with ATP7A-Flag WT, and mutants C1000R and
A1362D, and cells were cultured for 48 h at 37 or 30C. Protein
lysates (30 lg) were subjected to Western-blot analysis using the
antibodies indicated. c HEK293T cells were transfected with ATP7A-
Flag WT, and mutants C1000R and A1362D, and cultured at 30C.
Cells were incubated overnight under basal conditions or with
150 lM CuCl2. Cells were subsequently analyzed by indirect
confocal immunofluorescence using antibodies against the Flag-tag
(green) and p230 (red). Nuclei were stained with DAPI (blue). Bars:
10 lm. d Induction of the copper reporter was measured in HEK293T
cells transiently transfected with the MRE-luciferase reporter,
together with the ATP7A-Flag WT or mutant constructs C1000R
and A1362D. Cells were cultured at 30C, and incubated overnight
with 40 lM CuCl2. MRE-luciferase copper reporter activities are
expressed as fold induction relative to WT. Values are ±SD
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binding site for COMMD1 to ATP7A was mapped to the
COMM domain of COMMD1 (a.a. residues 119–190;
Fig. 6b), a sequence shared by all ten members of the
COMMD protein family. ATP7A domains interacting with
COMMD1 were restricted to the N-terminus (a.a. 1–654)
and to the cytosolic loop located between trans-membrane
domain (TMD) 6 and 7 (a.a. 1,008–1,368) (Fig. 6c). Since
the N-terminus of ATP7A is involved in copper binding,
we determined whether the interaction between ATP7A
and COMMD1 depended on copper. Upon excess copper
or copper depletion by means of BCS, binding of ATP7A
to COMMD1 was unaltered while the interaction with
ATOX1 could only be detected in conditions of excess
copper, suggesting that COMMD1 binds to ATP7A in a
copper-independent fashion (data not shown). Altogether,
we here illustrate that COMMD1 expression modulates the
protein level of both ATP7A WT and mutants, and sub-
sequently cellular copper homeostasis.
COMMD1 ameliorates copper exporting function
of ATP7A mutants
We continued to examine the effect of COMMD1 on the
subcellular localization and copper-transporting capacity of
ATP7A mutant proteins. Similar to the conditions for cel-
lular growth at 30C, overexpression of COMMD1 induced
a marked change in the localization of the mutants C1000R
and A1362D from the TGN to the cell periphery and PM,
respectively (Fig. 7). COMMD1 did not affect the locali-
zation of the L873R and N1304S mutants (data not shown).
Additionally, no effect of COMMD1 on the cellular local-
ization of ATP7A was established (Supplementary Fig. 2).
Interestingly, as a consequence of improved protein
expression and localization, COMMD1 ameliorated the
copper exporting function of the ATP7A mutants as
reflected by decreased induction of the copper reporter
activity (Fig. 8a). Indeed, upon co-expression of COM-
MD1, a significant reduction in the copper reporter activity
(approximately 29 and 36%) was observed in cells
expressing C1000R or N1304S mutant proteins, respec-
tively (Fig. 8a). Exogenous COMMD1 in cells expressing
mutants L873R and A1362D resulted in a trend towards an
improved copper exporting capacity, although these chan-
ges were not significant. In line with these results,
downregulation of COMMD1 expression led to a significant
further increase in the induction of copper reporter activity
for almost all ATP7A mutants (Fig. 8b).
Discussion
MD is caused by mutations in the ATP7A gene, however,
the molecular consequence of these mutations is still
unclear [5–10]. Here, we investigated four mutations in
ATP7A associated with three distinct MD phenotypes;
classical MD (severe MD), mild MD with long survival,
and OHS. The characteristics of the selected ATP7A
mutants on protein expression, intracellular localization,
and copper transport were studied, and summarized in
Table 2. Our most important observation was the clear
improvement of the copper-transporting function of some
of these ATP7A mutants in response to cellular growth at a
low temperature (30C) and upon COMMD1 expression.
Two of the four mutations studied (C1000R and
A1362D) resulted in decreased expression of the mutant
ATP7A protein. This reduced expression was associated
with enhanced proteasomal degradation rates, presumably
as a result of protein misfolding. Indeed, improving protein
folding by cellular growth at 30C resulted in a significant
increase in the protein expression of these mutants, and
almost completely restored their copper transport activity.
These findings are consistent with previous findings on
other P-type ATPases, including ATP7B and ATP8B1 [13,
26]. Whereas misfolding of proteins is frequently
Fig. 5 COMMD1 improves ATP7A protein expression. a Effect of
COMMD1 on ATP7A WT and mutant expression was studied in
HEK293T cells expressing EV, ATP7A-Flag WT, or mutant proteins
in combination with HA-COMMD1. Protein lysate (30 lg) was
analyzed by IB using indicated antibodies. b mRNA abundance of
ATP7A-Flag WT or mutants, expressed in HEK293T cells, in absence
of presence of HA-COMMD1 was analyzed by means of qRT-PCR as
described in ‘‘Materials and methods’’. The data represent
mean ± SD of triplicate measurements for each condition. The data
were corrected for transfection efficiency and GAPDH expression,
and normalized to WT–EV. c HEK293T cells were stably transfected
with pSUPER- RETRO vectors encoding non-specific shRNA
(shControl) or shRNA against COMMD1 (shCOMMD1) together
with ATP7A-Flag WT or mutant constructs. shRNA-mediated
depletion of COMMD1 expression in HEK293T cells resulted in
decreased protein expression of ATP7A-Flag WT and mutants
visualized using immunoblot analysis (IB). Samples were analyzed
on separate membranes (NT, WT, and L873R; and C1000R, N1304S,
and A1362D). d ATP7A expression was analyzed in HEK293T cells
upon shRNA-mediated depletion of COMMD1 expression (shControl
vs. shCOMMD1) and in MEFs, isolated from wild-type mice (WT)
and mice deficient for Commd1 (KO), by IB using the indicated
antibodies. e Induction of the copper reporter was measured in
HEK293T cells stably transfected with pSUPER- RETRO vectors
encoding non-specific shRNA (shControl) or shRNA against COM-
MD1 (shCOMMD1) with indicated concentration ATP7A-flag-myc
after overnight incubation with 40 lM CuCl2. NT non-transfected.
MRE-luciferase copper reporter activities are expressed as fold
induction relative to shControl. Values are ±SD. * indicates a
significantly different value compared to shControl cells (*p \ 0.05).
f Lysyl oxidase activity was determined in shControl and
shCOMMD1 transfected HEK293T cells, and WT and Commd1
KO MEFs after overnight incubation with 10 and 50 lM BCS or 0,
10, and 50 lM CuCl2. Values represent lysyl oxidase activity relative
to shControl at basal conditions. Values are ±SD. *, **, and ***
indicate significantly different values compared to shControl and
COMMD1 KO cells, respectively (*p \ 0.05, **p \ 0.01, and
***p \ 0.005)
c
158 W. I. M. Vonk et al.
123
accompanied by aberrant intracellular localization, the
ATP7A C1000R and A1362D mutants were properly
localized to the TGN, but failed to translocate to the plasma
membrane upon increased medium copper concentrations
(previously shown for C1000R by [27]). In contrast to
ATP7B and ATP8B1, no effect of the pharmacological
chaperones 4-PBA and curcumin on ATP7A C1000R and
A1362D mutant function was observed. Yet, similar to
4-PBA and curcumin, other compounds have been descri-
bed as enhancing protein folding and stability (e.g.,
dimethyl sulfoxide (DMSO), trimethylamine N-oxide
(TMAO), and glycerol), and therefore it might be inter-
esting to evaluate their potential in improving ATP7A
expression and function.
As a consequence of the mutations L873R and N1304S,
associated with severe MD and OHS, respectively, the
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subcellular localization of these ATP7A mutant proteins
was disturbed, and the copper export capacity was almost
completely abolished. The expression of these mutant
proteins was, however, comparable to ATP7A WT or even
enhanced. These results on mutant L873R are in line with
the data recently published by Petris et al. [27]. Consistent
Fig. 6 ATP7A interacts with COMMD1. a HEK293T cells were
transiently transfected with EV or with constructs encoding ATP7A-
Flag WT and mutants, GST only or COMMD1-GST as indicated
above the figure. Cells were lysed and a GST pull-down assay was
performed under basal conditions and analyzed as described in
Fig. 1d. b HEK293T cells were transiently transfected with constructs
encoding GST only, COMMD1-GST full-length (F.L.), N-terminal
part (a.a. 1–118) or C-terminal region (COMM domain; a.a. 119–190)
in combination with ATP7A-Flag. Cells were lysed and a GST pull-
down assay was performed and analyzed as described in Fig. 1d.
c HEK293T cells were transiently transfected with constructs
encoding COMMD1-GST and ATP7A-Flag N-terminal sequence
(a.a. 1–164), internal loop TMD4-5 (a.a. 795–944), internal loop
TMD6-7 (a.a. 1,008–1,368) or C-terminal region (a.a. 1,411–1,500).
Cells were lysed, and a GST pull-down assay was performed and
analyzed as described in Fig. 1d
Fig. 7 Copper-induced trafficking of ATP7A mutants is largely
restored by COMMD1. Localization of ATP7A mutants C1000R and
A1362D was determined in HEK293T cells, transiently transfected
with EV or HA-COMMD1. Cells were incubated overnight under
basal conditions or with 150 lM CuCl2. Cells were subsequently
analyzed by indirect confocal immunofluorescence using antibodies
against the Flag-tag (green). Nuclei were stained with DAPI (blue).
Bars: 10 lm
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with the notion that these mutations are located in highly
conserved functional domains essential for ATPase activity
of the copper pump, we suggest that they may not induce
aberrant folding, but rather result in a protein with severely
affected or completely abolished copper-transporting
activity. The aberrant expression of these proteins at the
cell periphery under copper depleted conditions would
explain the disrupted copper transfer into the secretory
pathway for the biosynthesis of copper-dependent
enzymes. However, in contrast to mutant L873R, N1304S
mainly resides in the cell periphery and is to some extent
also localized at the PM under copper-depleted or basal
conditions. Additionally, in excess copper, this mutant
shows a relatively normal copper response. These data
suggest that this mutation does not completely abrogate the
biosynthetic function of ATP7A, which correlates perfectly
with its mild atypical Menkes disease phenotype. However,
generally, it is currently still challenging to identify any
genotype-phenotype correlation in MD patients, since a
third of the mutations described are de novo, and there is
inter- and intra-familial variability. For example, the
A1362D mutation is associated with mild MD as well as
with OHS in two different families [6, 35]. In addition, the
R844H mutation has been identified in patients in one
family with both a classical MD and mild MD phenotype
[6, 36, 37], whereas S637L and A1362V mutations are
associated with all three MD phenotypes both within and
between families [35, 38, 39]. The mechanisms behind
these phenotypic variations are unknown, but they point to
genetic and/or environmental factors that modulate disease
severity.
Our data also demonstrate a novel role for COMMD1 in
the protein expression and function of ATP7A mutant
proteins. COMMD1 expression enhanced ATP7A levels,
improved the subcellular localization, and ameliorated the
copper exporting capacities of the ATP7A mutants. Since
COMMD1 expression and cellular growth at 30C both
improved the molecular function of ATP7A mutants in an
almost similar manner, we propose that COMMD1 might
be involved in protein folding of ATP7A, and consequently
in ATP7A stability, expression and function. Since
decreased expression of COMMD1 clearly exacerbates the
impaired function of ATP7A mutant proteins, it would be
interesting to determine whether genetic variants of
COMMD1 are associated with distinct MD phenotypes. We
further evidently demonstrated that loss of COMMD1
expression attenuates ATP7A protein level and cellular
copper homeostasis, indicating COMMD1 as novel mod-
ulator of ATP7A function.
In conclusion, in addition to mislocalization, our study
clearly demonstrates that a number of mutations in ATP7A
also display a reduced protein expression, most likely as a
result of misfolding. Improving the protein folding ame-
liorates the copper exporting activity, and, depending on
the molecular consequence of the mutation, might provide
a new direction for therapeutic strategies to treat MD.
Additionally, we also show a novel role for COMMD1 in
regulating the copper-transporting function of ATP7A WT
Fig. 8 COMMD1 partly ameliorates the copper-transporting function
of ATP7A mutants. a Induction of copper reporter activity measured
in HEK293T cells transiently transfected with the MRE-luciferase
reporter in combination with ATP7A-Flag WT or mutant, EV and
HA-COMMD1 constructs as indicated. Cells were incubated over-
night with 40 lM CuCl2 concentrations. MRE-luciferase reporter
activities are expressed as fold induction relative to WT. Values are
±SD. * and ** indicate significantly different values compared to EV
transfected cells (*p \ 0.05, **p \ 0.005). b Induction of copper
reporter was examined in HEK293T cells stably transfected with
pSUPER- RETRO vectors encoding shControl or shCOMMD1, and
the MRE-luciferase reporter in combination with ATP7A-Flag WT or
mutant constructs as indicated. The assay was performed as described
in Fig. 8a. * indicates significantly different values compared to
shControl transfected cells (*p \ 0.05)
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and four ATP7A mutants associated with MD, and impli-
cate COMMD1 as a potential modifier in MD
pathogenesis.
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